NCT04722627

Study of AT-752 in Healthy Subjects

A First-in Human, Randomized, Double-blind, Placebo Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AT-752 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 65 (actual)
• Sponsor: Atea Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-752 in healthy subjects

Detailed description

A First-in Human, Randomized, Double-blind, Placebo controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AT-752 in Healthy Subjects

Conditions

• Dengue

Interventions

Type	Name	Description
DRUG	AT-752	Parallel Assignment
DRUG	Placebo	Parallel Assignment

Timeline

• Start date: 2021-03-09
• Primary completion: 2021-11-14
• Completion: 2021-11-14
• First posted: 2021-01-25
• Last updated: 2022-10-17

Locations

1 site across 1 country: Australia